Physician profile
Evelyn Eccles
NPI 1366533689
$6,921.85
in general payments reported to CMS, 2019-2025
36 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $532 · 2021: $1,154 · 2022: $1,209 · 2023: $815 · 2024: $1,267 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,305.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,462.54 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $941.73 | 2019-2025 | |
| Lilly USA, LLC | $813.19 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $571.77 | 2019-2023 | Aimovig |
| Abbvie INC. | $365.15 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $356.60 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $312.00 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $291.54 | 2022 | |
| Mylan Specialty L.P. | $204.04 | 2021-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $198.57 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $186.66 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.91 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.34 | 2019-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceuticals, INC. | $129.99 | 2020-2021 | |
| Axsome Therapeutics, INC. | $99.24 | 2025 | Auvelity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $88.64 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $85.17 | 2022-2024 | Rexulti |
| Sanofi Pasteur INC. | $63.23 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $51.70 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $42.91 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $41.68 | 2019-2020 | |
| Owp Pharmaceuticals, INC. | $40.46 | 2024-2025 | Subvenite |
| Nestle Healthcare Nutrition INC. | $29.70 | 2021 | |
| Verona Pharma, INC. | $28.36 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $24.29 | 2021 | |
| Esperion Therapeutics, INC. | $22.33 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.84 | 2023 | Quviviq |
| Abbott Laboratories | $20.46 | 2021 | |
| Biomarin Pharmaceutical INC. | $17.13 | 2024 | Voxzogo 1.2mg |
| Cranial Technologies, INC | $16.50 | 2025 | Doc Band |
| Viatris Specialty LLC | $14.41 | 2025 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $14.02 | 2025 | Zoryve |
| Lundbeck LLC | $13.42 | 2022 | |
| Merck Sharp & Dohme LLC | $12.51 | 2019 | |
| Indivior INC. | $11.22 | 2021 | |
| Daiichi Sankyo INC. | $10.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Eccles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.